SW-100

SW-100, a selective histone deacetylase 6 (HDAC6) inhibitor with an IC50 of 2.3 nM, shows at least 1000-fold selectivity for HDAC6 relative to all other HDAC isozymes. SW-100 displays a significantly improved ability to cross the blood-brain-barrier[1].

Signaling Pathways >> Cell Cycle/DNA Damage >> HDAC

Research Areas >> Neurological Disease

Signaling Pathways >> Epigenetics >> HDAC

HDAC1:5.23 μM (IC50)

HDAC2:32.8 μM (IC50)

HDAC3:29.5 μM (IC50)

HDAC4:10.9 μM (IC50)

HDAC5:4.07 μM (IC50)

HDAC6:2.3 nM (IC50)

HDAC7:4.55 μM (IC50)

HDAC8:3.72 μM (IC50)

HDAC9:3.46 μM (IC50)

HDAC10:26.2 μM (IC50)

HDAC11:5.72 μM (IC50)

SW-100 (0.01-10 µM; 48 hours) shows obvious increase in the acetylated α-tubulin levels in a dose-dependent manner[1]. Western Blot Analysis[1] Cell Line: HEK293 cells Concentration: 0.01, 0.1, 1, 10 µM Incubation Time: 48 hours Result: Showed obvious increase in the acetylated α-tubulin levels in a dose-dependent manner.

SW-100 (20 mg/kg; i.p.; twice a day for two days) ameliorates several memory and learning impairments including novel object recognition, temporal ordering, and coordinate and categorical spatial processing in mouse model of Fragile X syndrome[1]. Animal Model: 8-10 weeks old C57BL/6 mice (Fmr1-/- mice)[1] Dosage: 20 mg/kg Administration: Intraperitoneal injection; twice a day for two days Result: Ameliorated several memory and learning impairments including novel object recognition, temporal ordering, and coordinate and categorical spatial processing in Fmr1-/- mice。

[1]. Kozikowski AP, et al. Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and LearningImpairments in a Mouse Model of Fragile X Syndrome. ACS Chem Neurosci. 2019 Mar 20;10(3):1679-1695.